CNS Cancers

‘Substantial Improvements’ in the Treatment of Glioblastoma

News articles about Senator John McCain’s diagnosis of glioblastoma accurately describe glioblastoma as aggressive and having a poor prognosis. But as Walter J. Curran, Jr, MD...

Gastrointestinal Cancer

‘Sidedness’ in Colon Cancer: Using the Data in the Clinic

The evidence from clinical trials has established that “side matters” when it comes to colorectal cancer outcomes. How do clinicians use this information in their practices? Christina Wu...

Hematologic Malignancies

Combination of Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Relapsed or Refractory Ph-Negative ALL

In a single-center phase II trial reported in JAMA Oncology, Jabbour et al found that the combination of inotuzumab ozogamicin (Besponsa) and low-intensity chemotherapy produced promising...


Advertisement

More Top Stories

Supportive Care

Jane McNeil Beith, MD, PhD, on Reducing Fear in Cancer Survivors

Prostate Cancer
Kidney Cancer
Bladder Cancer

Maha Hussain, MD, FACP, FASCO, Credits Collaboration for Her Contributions to Genitourinary Cancer

Internationally recognized genitourinary oncologist Maha Hussain, MD, FACP, FASCO, was born and reared in Baghdad, Iraq. “I came from a family that stressed the value of higher education and especially medicine. I have three uncles who are physicians, and my father encouraged my three siblings and...

Advertisement

New ASCO Guideline Aims to Improve Clinician Communication With Patients

A new guideline from ASCO published by Gilligan et al in the Journal of Clinical Oncology outlines best practices for cancer clinicians when communicating with patients and their loved ones. The Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline...

Pancreatic Cancer

David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective

ASTRO Welcomes New Officers to Board of Directors

THE MEMBERS of the American Society for Radiation Oncology (ASTRO) have elected three new officers to ASTRO’s Board of Directors and three members to serve on the medical society’s Nominating Committee. The newly elected President-Elect, Health Policy Council Vice-Chair, Science Council Vice-Chair, ...

Lung Cancer

Non–Small Cell Lung Cancer: Emerging Concepts for Checkpoint Inhibitors

With checkpoint inhibitors vitally important in the treatment of advanced non–small cell lung cancer (NSCLC), clinicians must become familiar with the nuances of their use. At the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, Suresh S. Ramalingam, MD,...

First-Line Gemcitabine/Docetaxel vs Doxorubicin in Advanced Soft-Tissue Sarcoma

In the UK-Swiss phase III GeDDiS trial, the combination of gemcitabine and docetaxel did not significantly improve progression-free survival vs doxorubicin in first-line treatment of locally advanced or metastatic soft-tissue sarcoma. Findings were reported in The Lancet Oncology by Seddon et al....

Symptom Management
Pain Management

Peter Hoskin, MD, on Spinal Compression: Results From the SCORAD III Trial

Award for Early Career Scientists in New York: Applications Open October 2, 2017

The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will open for applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000/year—for up to 3 years—to enable them to pursue...

Advertisement

Addition of Bortezomib to R-CHOP in Non–Germinal Center B-Cell–Like Lymphoma

A phase II trial reported in the Journal of Clinical Oncology by Leonard et al showed no significant progression-free survival benefit of adding bortezomib (Velcade) to R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in previously untreated patients with...